CDK4/6 inhibitor

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.